Bide Pharmatech Co. Ltd. A (688073) - Total Assets
Based on the latest financial reports, Bide Pharmatech Co. Ltd. A (688073) holds total assets worth CN¥2.54 Billion CNY (≈ $371.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Bide Pharmatech Co. Ltd. A to assess the company's total reinvestment commitment from operating cash flow.
Bide Pharmatech Co. Ltd. A - Total Assets Trend (2020–2025)
This chart illustrates how Bide Pharmatech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Check Bide Pharmatech Co. Ltd. A earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Bide Pharmatech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Bide Pharmatech Co. Ltd. A's total assets of CN¥2.54 Billion consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 37.4% |
| Accounts Receivable | CN¥253.44 Million | 10.1% |
| Inventory | CN¥962.01 Million | 38.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥4.93 Million | 0.2% |
| Goodwill | CN¥7.56 Million | 0.3% |
Asset Composition Trend (2020–2025)
This chart illustrates how Bide Pharmatech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Bide Pharmatech Co. Ltd. A.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bide Pharmatech Co. Ltd. A's current assets represent 91.6% of total assets in 2025, an increase from 85.9% in 2020.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2025, up from 17.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 38.2% of total assets.
Bide Pharmatech Co. Ltd. A Competitors by Total Assets
Key competitors of Bide Pharmatech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Bide Pharmatech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.43 | 2.88 | 7.65 |
| Quick Ratio | 4.37 | 1.52 | 5.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.03 Billion | CN¥1.11 Billion | CN¥1.91 Billion |
Bide Pharmatech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Bide Pharmatech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.56 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | CN¥2.52 Billion |
| Market Capitalization | $603.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bide Pharmatech Co. Ltd. A's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bide Pharmatech Co. Ltd. A's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bide Pharmatech Co. Ltd. A (2020–2025)
The table below shows the annual total assets of Bide Pharmatech Co. Ltd. A from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.52 Billion ≈ $368.29 Million |
+4.08% |
| 2024-12-31 | CN¥2.42 Billion ≈ $353.83 Million |
+0.12% |
| 2023-12-31 | CN¥2.42 Billion ≈ $353.39 Million |
+2.37% |
| 2022-12-31 | CN¥2.36 Billion ≈ $345.23 Million |
+160.36% |
| 2021-12-31 | CN¥906.13 Million ≈ $132.60 Million |
+70.36% |
| 2020-12-31 | CN¥531.90 Million ≈ $77.83 Million |
-- |
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.